Table 1. Summary of cost for patient group and type of treatment.
| Swiss Franc [CHF] | all (SD) | DME (vs. AMD) (95% CI) | p-value | RVO (vs. AMD) (95% CI) | p-value |
|---|---|---|---|---|---|
| Av. global cost /month | 2023.44 (2684.13) | +2174.88 (1094.50–3255.27) | <0.001 | +284.71 (-866.73–1436.15) | 0.627 |
| Av. ophthalmologic cost /month | 1415.61 CHF (957.72 | + 188.13 (-180.85–557.11) | 0.316 | - 0.40 (-393.65–392.85) | 0.998 |
| Ranibizumab vs. Aflibercept (95% CI) | p-value | ||||
| Comparison of treatments for AMD | |||||
| Av. global cost /month | 1711.60 (1305.36) | -679.77* (-2052.51–692.97) | 0.330 | ||
| Av. ophthalmologic cost /month | 1350.74 (886.29) | -264.37* (-1163.76–635.22) | 0.563 |
*adjusted for patients’ age, female gender, baseline visual acuity and number of injections.